Technological advances have allowed us to interrogate the human genome in ways that were never possible before. These tests can help us better predict and diagnose disease and provide optimal outcomes with current therapy. Singapore has initiated a National Precision Medicine programme (NPM) in 2017. In Singapore’s Research Innovation and Enterprise (RIE) 2025 plan, the NPM is a national translational programme prioritised under the Human Health Potential (HHP) domain. One of the goals is to facilitate the incorporation of genetic/genomic tests into clinical pathways that improve patient outcomes while maintaining sustainable per capita cost, optimizing healthcare experiences for both providers and patients.
- One-time Funding Opportunity for up to 5 CIPs with an indicative funding of $1.5M each over a 2-year period.
- Additional supplementary funding of up to $3M for collaborative supplementary projects between shortlisted applicants.
- Register now for our Virtual Roadshow to find out more!
- Join PRECISE_Clinical Innovation LinkedIn group to get a sneak peek into upcoming initiatives and provide feedback on the draft CIP application form.
To achieve this goal, the upcoming call will be designed as a collaborative programme to foster partnerships between various stakeholders within the community and galvanise collective action to address issues in the areas outlined below:
- Evaluation of costs and benefits for the incorporation of genetic/genomic tests into clinical pathways within the local healthcare system;
- Reduce variability and/or duplication of clinical workflows/practices across clinical areas and healthcare institutes/clusters as these may have an impact on costs and scalability of incorporating genetic/genomic tests into clinical pathways within the local healthcare system.
Areas of Interest
- Specific areas of interest include conditions or disease phenotypes that require the use of genetic/genomic tests in its diagnosis, management and/or treatment; and involving germline mutations, or combining both germline and somatic mutations.
- Focus will be on clinical pathways that will result in a change to the current screening and/or therapeutic strategy based on the result of the genetic/genomic test. There should be some prior belief that the strategy is likely to improve patient outcomes, reduce healthcare utilisation and/or costs, and/or enhance efficiency in healthcare delivery, preferably supported by established guidelines or studies where available.
- We favour: Proposals that involve pathways where there is uncertainty about the optimal way to implement the pathway in Singapore, or uncertainty about the acceptance of clinicians and/or patients to the new pathway in Singapore, or where we need additional data to evaluate costs and benefits of the new pathway in the local healthcare system.
- We do not favour and will not consider: Proposals that involve experimental strategies of unclear efficacy or have not been approved for use in humans for the conditions or disease phenotypes under consideration, or proposals that involve genotyping cohorts to study gene-disease association without addressing the uncertainties outlined in point b(i)
- The Corresponding Principal Investigator (PI) must hold a primary appointment in, and be salaried by a public healthcare institution (PHI), Academic Medical Centre, an Institute of Higher Learning or Research Institute in Singapore.
- Project teams must include a Clinical co-PI who is prepared to champion implementation of the clinical pathway in the healthcare system and drive pilot implementation of the programme, and must include a second co-PI who is experienced in health economics and/or health technology assessment to support economic evaluation of the programme. Project teams are also expected to work closely with PRECISE health economics team and its network for the implementation and economic evaluation of the programme.
- A virtual roadshow will be held on 26 July 2021, 2pm-4pm, to introduce and share more details about the call before its official launch.
- The virtual roadshow will provide a platform for participants to pose clarifying questions related to the call.
- Applicants are strongly encouraged to register and participate in the virtual roadshow before submitting a proposal.
|Grant call launch (application start date)||End Jul 2021|
|Application submission deadline||End Sep 2021|
|Application review & shortlisting||End Sep – end Oct 2021|
|Notification of shortlisting outcome to all applicants||End Oct 2021|
|For shortlisted applicants only|
|Proposal workshop (compulsory attendance for co-PIs)||Mid Nov 2021|
|Submission deadline for revised proposals||Mid Dec 2021|
|Presentation at Final Review||Mid Jan 2022|
|For successful applicants|
|Funding decision||Jan 2022 – Feb 2022|
|Letter of award||End Feb 2022|
- Up to 5 projects will be awarded, for a period of 2 years (non-extendable).
- Indicative funding of up to S$1.5 million to support the cost of programme implementation and evaluation for each project; additional supplementary funding quantum of up to S$3 million will be available to support collaborative supplementary project(s) between shortlisted applicants (there is no provision of indirect costs from the grant).
- Proposals should be submitted through email, using the CIP application form. Detailed guidance on the application process, final call information and call for proposal documents will be published on the PRECISE website with the formal launch of the call.
- We invite applicants to join our LinkedIn group (PRECISE_Clinical Innovation) to be kept abreast and be offered a sneak peek into our initiatives for the call – including the opportunity to share your feedback to the draft CIP application form.
- Feel free to email us at CIP@precise.cris.sg to leave us your questions and connect.